Clinical Trial Update: APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of APG-1387 in combination with chemotherapy for advanced pancreatic adenocarcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• APG-1387 (APG-1387)

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: Advanced Pancreatic Cancer | Phase 1, Phase 2 | Status: TERMINATED